News

BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020

BenevolentAI has been selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.

The annual Fierce 15 competition whittles down nominations from around the globe to recognise fifteen medical technology companies leading in innovation and creativity. This accolade is demonstrative of a year of embracing new milestones at Benevolent, and a testament to our cutting-edge technology and powerful collaborations. 

As Conor Hale, Associate Editor of Fierce Medtech commented: “Each member of this year’s class of Fierce 15 stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes that much more significant.”

Despite the disruption caused by the global pandemic and accompanying lockdowns, 2020 saw us achieve impactful results. Our COVID-19 research, which began in January 2020, led to us identifying baricitinib as a potential treatment across one weekend. Just nine  months later, baricitinib became one of the few coronavirus treatments approved by the FDA for emergency use. 

In parallel, we continued to push ahead with our AstraZeneca collaboration. In April 2020, we delivered the first output of hypotheses for CKD; and more recently, AstraZeneca selected the first AI-generated CKD target for their portfolio after it was biologically validated via their rigorous experimental testing. Our  data-driven approach integrated AstraZeneca’s disease experts alongside our data scientists, bioinformaticians and machine learning engineers. This cross-functional connection continues to yield new ideas and leads us to generating  novel, higher quality targets whilst reducing the time traditionally taken  to discover a potential drug candidate. 

Simultaneously, we continued to deepen and strengthen our internal pipeline of drug programmes. In February 2021 we dosed the first patient in the randomised clinical trial of BEN-2293, a molecule we designed and developed to treat atopic dermatitis. We hope this treatment will address the inflammation and itch that makes the disease so difficult to endure. 

The drug discovery industry still faces significant challenges. It is expensive and high risk, with long R&D cycles, which cost today’s patients. There has never been a more critical time to play a part in changing this, and by fusing human and machine intelligence we believe we can help to shorten this complex process and create  treatments which are more effective for patients.

Is our goal an ambitious one? Absolutely. But we believe we have only just started to see the impact of our technology and approach and are eager to see what achievements and progress lie ahead. We are delighted to be recognised amongst fellow tech pioneers by Fierce Medtech at this stage of our journey.


More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021